Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference

Rhea-AI Summary

Silence Therapeutics (Nasdaq: SLN) announced its participation in the H.C. Wainwright BioConnect Virtual Conference scheduled for January 10-13, 2022. The company will feature in a fireside chat, with an on-demand presentation available from January 10 at 7:00 AM ET / 12:00 PM GMT via its Investors section on the Silence website. This engagement highlights Silence's commitment to addressing unmet medical needs through innovative siRNA therapeutics, including SLN360 for cardiovascular risk and SLN124 for rare hematological diseases.

Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Virtual Conference

5 January 2022

LONDON, Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will participate in a fireside chat during the H.C. Wainwright BioConnect Virtual Conference on January 10 – 13, 2022.

The on-demand presentation will be available beginning on Monday, January 10 at 7:00am ET / 12:00pm GMT and can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available on the Company’s website following the conference.

Enquiries:

Silence Therapeutics plc Gem Hopkins, Head of IR and Corporate Communications ir@silence-therapeutics.com US Media Relations MKC Strategies Mary Conway mconway@mkcstrategies.com	Tel:  +1 (646) 637-3208 Tel: +1 (516) 606-6545
European Media Relations Consilium Strategic Communications Mary-Jane Elliott/ Angela Gray / Chris Welsh silencetherapeutics@consilium-comms.com	Tel: +44 (0) 20 3709 5700

About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address rare hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.

FAQ

When will Silence Therapeutics participate in the BioConnect Virtual Conference?

Silence Therapeutics will participate in the H.C. Wainwright BioConnect Virtual Conference from January 10 to 13, 2022.

What time will the on-demand presentation by Silence Therapeutics be available?

The on-demand presentation will be available starting January 10, 2022, at 7:00 AM ET / 12:00 PM GMT.

Where can I access the Silence Therapeutics presentation during the conference?

The presentation can be accessed via the Investors section of the Silence Therapeutics website.

What are the main focuses of Silence Therapeutics' research?

Silence Therapeutics focuses on developing siRNA therapeutics for cardiovascular risks and rare hematological diseases.

What is the significance of SLN360 and SLN124 for Silence Therapeutics?

SLN360 targets high lipoprotein(a) levels to reduce cardiovascular risks, while SLN124 addresses rare hematological diseases.